In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant

A.M. Bergman; P.P. Eijk; van Hapere Ruiz; K. Smid; G. Veerman; I. Hubeek; P. van den IJssel; B. Ylstra; G.J. Peters

doi:https://doi.org/10.1158/0008-5472.CAN-05-0989

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant

A.M. Bergman, P.P. Eijk, van Hapere Ruiz, K. Smid, G. Veerman, I. Hubeek, P. van den IJssel, B. Ylstra, G.J. Peters

Amsterdam UMC

Research output: Contribution to journal › Article › Academic › peer-review

170 Citations (Scopus)

Original language	English
Pages (from-to)	9510-9516
Journal	Cancer research
Volume	65
Issue number	20
DOIs	https://doi.org/10.1158/0008-5472.CAN-05-0989
Publication status	Published - 2005

Access to Document

https://doi.org/10.1158/0008-5472.CAN-05-0989

Cite this

@article{9b5bedbd77d846aeae8d6e6b144bf0f8,

title = "In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant",

author = "A.M. Bergman and P.P. Eijk and Ruiz, {van Hapere} and K. Smid and G. Veerman and I. Hubeek and {van den IJssel}, P. and B. Ylstra and G.J. Peters",

year = "2005",

doi = "https://doi.org/10.1158/0008-5472.CAN-05-0989",

language = "English",

volume = "65",

pages = "9510--9516",

journal = "Cancer research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "20",

}

TY - JOUR

T1 - In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant

AU - Bergman, A.M.

AU - Eijk, P.P.

AU - Ruiz, van Hapere

AU - Smid, K.

AU - Veerman, G.

AU - Hubeek, I.

AU - van den IJssel, P.

AU - Ylstra, B.

AU - Peters, G.J.

PY - 2005

Y1 - 2005

U2 - https://doi.org/10.1158/0008-5472.CAN-05-0989

DO - https://doi.org/10.1158/0008-5472.CAN-05-0989

M3 - Article

SN - 0008-5472

VL - 65

SP - 9510

EP - 9516

JO - Cancer research

JF - Cancer research

IS - 20

ER -